Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
Go back to Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.79 -0.78 (21.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.57 | 52 Week High | $9.58 | |||
| Open | $2.99 | 52 Week Low | $2.34 | |||
| Day High | $3.05 | P/E | N/A | |||
| Day Low | $2.35 | EPS | $-0.34 | |||
| Volume | 2,735,455 | |||||
